ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VEEV Veeva Systems Inc

185.77
0.00 (0.00%)
Pre Market
Last Updated: 10:04:46
Delayed by 15 minutes
Share Name Share Symbol Market Type
Veeva Systems Inc NYSE:VEEV NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 185.77 0 10:04:46

Biopharma Leaders Shape the Future of Drug Development at Veeva R&D and Quality Summit Europe

21/05/2024 12:03pm

PR Newswire (US)


Veeva Systems (NYSE:VEEV)
Historical Stock Chart


From Jun 2024 to Jun 2024

Click Here for more Veeva Systems Charts.

Ascendis, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva to keynote sharing innovations to drive better patient outcomes

BARCELONA, Spain, May 21, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that leaders from Ascendis Pharma A/S, Bayer, Boehringer Ingelheim, Jazz Pharmaceuticals, Novo Nordisk, Sanofi, and Teva will be keynote speakers at Veeva R&D and Quality Summit, Europe, June 4-5 in Madrid, Spain. Life sciences professionals across the industry will come together to share how connected technologies across clinical, regulatory, safety, and quality are advancing innovations for patients.

Veeva Systems

As one of the largest gatherings of biopharma leaders in Europe, Veeva R&D and Quality Summit will bring together over 1,000 industry professionals to share learnings across more than 100 sessions. Bayer and Jazz Pharmaceuticals will join Rik Van Mol, senior vice president of Veeva Development Cloud, and Avril England, general manager of Veeva Vault, for the opening keynote to explore the future of development for new medicines and therapies.

The event's zone keynotes include:

  • Ascendis and Bayer, sharing strategies to reduce costs and accelerate trials with a connected platform.

  • Boehringer Ingelheim, detailing its shift toward data-centric regulatory information management.

  • Novo Nordisk, showing how it uses data and AI to transform clinical research.

  • Sanofi, explaining its innovative approach to advance quality through operational excellence.

  • Teva, providing insight into its rapid journey from disparate safety systems into one streamlined global solution.

A panel with Elpida Therapeutics CEO Terry Pirovolakis and Veeva experts will close the event with a discussion on how the industry can best accelerate the development of life-saving rare disease gene therapies.

"Connecting clinical, regulatory, safety, and quality is key to advancing the product lifecycle and delivering better outcomes for patients," says Rik Van Mol, senior vice president of Veeva Development Cloud. "At Veeva R&D and Quality Summit, biopharma leaders can connect, exchange ideas, and share new strategies to advance the industry forward together."

Veeva R&D and Quality Summit is open exclusively to life sciences professionals. Register and review the agenda at veeva.com/eu/Summit.

Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2024, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.

Contact:

Jeremy Whittaker
Veeva Systems
+49-695-095-5486
jeremy.whittaker@veeva.com

Logo - https://mma.prnewswire.com/media/1488285/Veeva_Systems_Logo.jpg 

Cision View original content:https://www.prnewswire.co.uk/news-releases/biopharma-leaders-shape-the-future-of-drug-development-at-veeva-rd-and-quality-summit-europe-302150491.html

Copyright 2024 PR Newswire

1 Year Veeva Systems Chart

1 Year Veeva Systems Chart

1 Month Veeva Systems Chart

1 Month Veeva Systems Chart

Your Recent History

Delayed Upgrade Clock